[go: up one dir, main page]

AU2002331898A1 - Induction of brown adipocytes by transcription factor nfe2l2 - Google Patents

Induction of brown adipocytes by transcription factor nfe2l2

Info

Publication number
AU2002331898A1
AU2002331898A1 AU2002331898A AU2002331898A AU2002331898A1 AU 2002331898 A1 AU2002331898 A1 AU 2002331898A1 AU 2002331898 A AU2002331898 A AU 2002331898A AU 2002331898 A AU2002331898 A AU 2002331898A AU 2002331898 A1 AU2002331898 A1 AU 2002331898A1
Authority
AU
Australia
Prior art keywords
nfe2l2
induction
transcription factor
brown adipocytes
adipocytes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002331898A
Inventor
Leslie P. Kozak
Jong S. Rim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Louisiana State University
Original Assignee
Louisiana State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Louisiana State University filed Critical Louisiana State University
Publication of AU2002331898A1 publication Critical patent/AU2002331898A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2002331898A 2001-09-24 2002-09-24 Induction of brown adipocytes by transcription factor nfe2l2 Abandoned AU2002331898A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32440001P 2001-09-24 2001-09-24
US60/324,400 2001-09-24
PCT/US2002/030266 WO2003026576A2 (en) 2001-09-24 2002-09-24 Induction of brown adipocytes by transcription factor nfe2l2

Publications (1)

Publication Number Publication Date
AU2002331898A1 true AU2002331898A1 (en) 2003-04-07

Family

ID=23263411

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002331898A Abandoned AU2002331898A1 (en) 2001-09-24 2002-09-24 Induction of brown adipocytes by transcription factor nfe2l2

Country Status (2)

Country Link
AU (1) AU2002331898A1 (en)
WO (1) WO2003026576A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005037232A2 (en) 2003-10-17 2005-04-28 Joslin Diabetes Center, Inc. Methods and compositions for modulating adipocyte function
EP1734963A4 (en) 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING MEN WITH METABOLIC AND ANTHROPOMETRIC DISORDERS
WO2006108023A2 (en) * 2005-04-04 2006-10-12 Joslin Diabetes Center, Inc. Methods and compositions for modulating necdin function
US20100150885A1 (en) 2005-06-01 2010-06-17 Joslin Diabetes Center, Inc. Methods and compositions for inducing brown adipogenesis
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009149279A2 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CA2741125A1 (en) 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
WO2010051206A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8476227B2 (en) 2010-01-22 2013-07-02 Ethicon Endo-Surgery, Inc. Methods of activating a melanocortin-4 receptor pathway in obese subjects
US9044606B2 (en) 2010-01-22 2015-06-02 Ethicon Endo-Surgery, Inc. Methods and devices for activating brown adipose tissue using electrical energy
US8895596B2 (en) 2010-02-25 2014-11-25 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
BR112013021236B1 (en) 2011-02-25 2021-05-25 Merck Sharp & Dohme Corp benzimidazole derivative compound, and, composition
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2015010935A (en) 2013-02-22 2015-10-29 Merck Sharp & Dohme Antidiabetic bicyclic compounds.
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP2016534043A (en) 2013-10-09 2016-11-04 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists useful for down-regulation of pro-inflammatory cytokines
US10080884B2 (en) 2014-12-29 2018-09-25 Ethicon Llc Methods and devices for activating brown adipose tissue using electrical energy
US10092738B2 (en) 2014-12-29 2018-10-09 Ethicon Llc Methods and devices for inhibiting nerves when activating brown adipose tissue
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE352561T1 (en) * 1997-05-30 2007-02-15 Dana Farber Cancer Inst Inc PGC-1, A NOVEL PPAR-GAMMA COACTIVATOR FROM BROWN ATI TISSUE
EP1153037A1 (en) * 1999-02-09 2001-11-14 Lexicon Genetics Incorporated Human uncoupling proteins and polynucleotides encoding the same

Also Published As

Publication number Publication date
WO2003026576A3 (en) 2003-06-26
WO2003026576A2 (en) 2003-04-03

Similar Documents

Publication Publication Date Title
AU2002331898A1 (en) Induction of brown adipocytes by transcription factor nfe2l2
AU2002306868A1 (en) Therapeutic combinations for cardiovascular and inflammatory indications
AU2002360988A1 (en) Adhesion inhibition of moulds
AU2002236528A1 (en) Uv-free curing of organic dielectrica
AU2002223504A1 (en) Heterologous expression of taxanes
AU2003303250A1 (en) Quantification of operational risks
AU2001245989A1 (en) Preparation of epothilone intermediates
AU2003275026A1 (en) Induction of insulin expression
AU2002341542A1 (en) Transcription factors of cereals
AU4497101A (en) Induction winding
AU2002303390A1 (en) Induction of apoptosis by cellular stress
AU2002337053A1 (en) Measuring transformer
AU2002366310A1 (en) Method of inducing apoptosis and compositions therefor
AU2002361763A1 (en) Method of reducing angiogenesis
AU2001287218A1 (en) The use of melatonin for induction of general anesthesia
AU2003296313A1 (en) Modulation of fetoprotein transcription factor expression
AUPR963401A0 (en) Methods for the enhancement of complex peaks
AU2002360974A1 (en) Novel use of alloys
AUPR539601A0 (en) Method of magnetic field measurement
AU2003283246A1 (en) Inductive flowmeter
GB0100151D0 (en) Methods of sputtering
AU7797000A (en) Reheating method by induction of thixotropic materials
AU2002321556A1 (en) Inhibition of replication factor c
HK1059039A (en) Induction of tolerance
AU2002228552A1 (en) Induction winding

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase